Biovica will attend the San Antonio Breast Cancer Symposium, an event that brings together oncology professionals from around the world. SABCS is the world’s leading breast cancer congress attracting more than 7,500 attendees from 90 countries.
Read more at sabcs.org
“At SABCS we will present new clinical study results in collaboration with two US Cancer Institutes. It will be the first evidence that DiviTum is a unique assay for fast and early efficacy evaluation of cell cycle regulating drugs. The results are highly promising for women with breast cancer and in line with Biovica’s ambition to contribute to a more optimal patient outcome. We look forward to meet our many US and international academic partners and to expand our collaborations with oncologists and pharmaceutical companies,” says Mattias Bergqvist, VP Marketing & Clinical Development.